Hyperinsulinemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hyperinsulinemia – Pipeline Review, H2 2016’, provides an overview of the Hyperinsulinemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hyperinsulinemia

The report reviews pipeline therapeutics for Hyperinsulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hyperinsulinemia therapeutics and enlists all their major and minor projects

The report assesses Hyperinsulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hyperinsulinemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hyperinsulinemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hyperinsulinemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eiger BioPharmaceuticals Inc

Heptares Therapeutics Ltd

Seneb BioSciences Inc

XOMA Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hyperinsulinemia Overview 6

Therapeutics Development 7

Pipeline Products for Hyperinsulinemia - Overview 7

Pipeline Products for Hyperinsulinemia - Comparative Analysis 8

Hyperinsulinemia - Therapeutics under Development by Companies 9

Hyperinsulinemia - Therapeutics under Investigation by Universities/Institutes 10

Hyperinsulinemia - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Hyperinsulinemia - Products under Development by Companies 13

Hyperinsulinemia - Products under Investigation by Universities/Institutes 14

Hyperinsulinemia - Companies Involved in Therapeutics Development 15

Eiger BioPharmaceuticals Inc 15

Heptares Therapeutics Ltd 16

Seneb BioSciences Inc 17

XOMA Corp 18

Hyperinsulinemia - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

exendin-(9-39) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

exendin-(9-39) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

SNB-2401 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

XOMA-358 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Hyperinsulinemia - Dormant Projects 35

Hyperinsulinemia - Product Development Milestones 36

Featured News & Press Releases 36

Oct 19, 2016: XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism 36

Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies 36

Sep 06, 2016: XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016 37

Jul 20, 2016: XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism 38

Jun 16, 2015: XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism (HI) 38

Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

Number of Products under Development for Hyperinsulinemia, H2 2016 7

Number of Products under Development for Hyperinsulinemia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Hyperinsulinemia – Pipeline by Eiger BioPharmaceuticals Inc, H2 2016 15

Hyperinsulinemia – Pipeline by Heptares Therapeutics Ltd, H2 2016 16

Hyperinsulinemia – Pipeline by Seneb BioSciences Inc, H2 2016 17

Hyperinsulinemia – Pipeline by XOMA Corp, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Hyperinsulinemia – Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for Hyperinsulinemia, H2 2016 7

Number of Products under Development for Hyperinsulinemia – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports